Full text is available at the source.
Abstract
GLP-1-based medications, including semaglutide and tirzepatide, have transformed obesity treatment since 2021.
- Semaglutide received approval for obesity treatment in the US in 2021 and in Europe in 2022.
- Tirzepatide, a dual-agonist, has shown greater effectiveness compared to semaglutide.
- There is limited survey data on the demographics of individuals using or considering these medications.
- The existing data lacks insights across various socioeconomic groups, BMI categories, and weight management experiences.
Simplified